NL-OMON44939已完成不适用
A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG232 in adult subjects with advanced solid tumors or multiple myeloma - Phase 1 study with AMG232 in adults with solid tumors or multiple myeloma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Men or women >/<= 18 years old;Pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment or for which no standard therapy is available or the subject refuses standard therapy;Subjects with tumors showing evidence of wild-type p53.;ECOG performance status of 3 months, in the opinion of the investigator.;Able to take oral medications.;Voor een volledig overzicht van alle inclusiecriteria verwijs ik u naar paragraaf 4.1 van het 20120106 protocol
排除标准
- •Prior bone marrow transplant;History or presence of hematological malignancies;Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure, unstable angina or cardiac arrhythmia requiring medication.;Active infection requiring intravenous antibiotics within 2 weeks of study enrollment (day 1).;Major surgery within 28 days of study day 1.;Voor een volledig overzicht van alle exclusiecriteria verwijs ik u naar paragraaf 4.2 van het 20120106 protocol
研究者
相似试验
暂停
1 期
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia (AML)JPRN-jRCT2031210152ocal Contact200
暂停
1 期
A Phase 1 Study of AMG 330 in Subjects With Myeloid MalignanciesRelapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic SyndromeJPRN-jRCT2071210044Contact Local256
已完成
1 期
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Multiple MyelomaRelapsed or Refractory Acute Myeloid LeukemiaJPRN-jRCT2080224749Amgen K.K.175
已完成
不适用
A first-in-human study to evaluate the safety and performance of placebo excipient-coated high-density microarray patches applied by an integrated application device.VaccinationsPublic Health - Other public healthACTRN12620000179932Vaxxas Pty Ltd43
尚未招募
1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteersAcromegalyDRKS00032263niversität Heidelberg vertreten durch das Universitätsklinikum95